Rangavajhula V[au] - Search Results

Save citations to file

Email citations

Your saved search

Your RSS Feed

Year	Number of Results
2012	1
2014	1
2015	1
2022	0

Page 1

Now that you want to take your HIV/AIDS vaccine/biological product research concept into the clinic: what are the "cGMP"?

Sheets RL, Rangavajhula V, Pullen JK, Butler C, Mehra V, Shapiro S, Pensiero M. Sheets RL, et al. Among authors: rangavajhula v. Vaccine. 2015 Apr 8;33(15):1757-66. doi: 10.1016/j.vaccine.2015.02.003. Epub 2015 Feb 16. Vaccine. 2015. PMID: 25698494 Free PMC article. Review.

A risk-based auditing process for pharmaceutical manufacturers.

Vargo S, Dana B, Rangavajhula V, Rönninger S. Vargo S, et al. Among authors: rangavajhula v. PDA J Pharm Sci Technol. 2014 Mar-Apr;68(2):104-12. doi: 10.5731/pdajpst.2014.00954. PDA J Pharm Sci Technol. 2014. PMID: 24668599

Considerations on Auditing and GxP Requirements along the Product Lifecycle.

Rönninger S, Schmitt S, Rangavajhula V, Hough E, Lyda J. Rönninger S, et al. Among authors: rangavajhula v. PDA J Pharm Sci Technol. 2012 Sep-Oct;66(5):396-402. doi: 10.5731/pdajpst.2012.00881. PDA J Pharm Sci Technol. 2012. PMID: 23035024

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results